Jan 08, 2025 8:00am EST RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
Dec 30, 2024 8:00am EST RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
Dec 11, 2024 8:00am EST RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
Dec 10, 2024 8:00am EST RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
Dec 05, 2024 8:00am EST RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
Nov 20, 2024 8:45am EST Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Nov 14, 2024 8:00am EST RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Sep 25, 2024 8:30am EDT RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
Sep 19, 2024 8:30am EDT RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
Aug 27, 2024 8:30am EDT RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
